https://www.selleckchem.com/pr....oducts/rocilinostat-
Moreover, the PD-L1 expression on tumor tissue was upregulated during treatment, predicting the limited benefit from immune-chemotherapy. This case report suggests that lorlatinib is a better choice than immune-chemotherapy in second-line setting for patients with similar genomic characteristics, and that monitoring the immune components during immunotherapy may help to predict disease response.The development of oncolytic viruses (OVs) has increased significantly in the past 20 years, with many candidates entering clinica
Like
Comment
Share
